Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

251.24USD
4:00pm EDT
Price Change (% chg)

$0.44 (+0.18%)
Prev Close
$250.80
Open
$249.48
Day's High
$251.80
Day's Low
$249.27
Volume
416,653
Avg. Vol
283,969
52-wk High
$258.50
52-wk Low
$109.23

SHPG.OQ

Chart for SHPG.OQ

About

Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in... (more)

Overall

Beta: 0.76
Market Cap (Mil.): $49,205.45
Shares Outstanding (Mil.): 196.51
Dividend: 0.51
Yield (%): 0.24

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 26.21 35.68 36.12
EPS (TTM): 9.57 -- --
ROI: 26.16 18.88 18.15
ROE: 37.75 19.60 18.97
Search Stocks

UPDATE 3-AbbVie profit beats estimates on surging Humira sales

July 25 - AbbVie Inc, which last week announced plans to buy Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly earnings on surging sales of its Humira treatment for rheumatoid arthritis.

25 Jul 2014

Actelion CEO seeks to diffuse takeover talk

ZURICH - Actelion Chief Executive Jean-Paul Clozel said he was determined to keep the Swiss biotech company independent, batting away speculation it could become the next takeover target for U.S. firms seeking lower taxes by relocating abroad.

22 Jul 2014

U.S. drugmaker AbbVie finally wins Dublin's Shire with $55 billion deal

LONDON - U.S. drugmaker AbbVie Inc bought Dublin-based Shire Plc on Friday in a 32 billion pound ($54.7 billion) deal that will allow it to slash its tax bill by relocating to Britain. | Video

18 Jul 2014

AbbVie’s Shire merger backed with 13.5 billion pound bridge loan

LONDON - U.S. drugmaker AbbVie’s 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

RLPC-AbbVie's Shire merger backed with 13.5 bln stg bridge loan

LONDON, July 18 - U.S. drugmaker AbbVie's 32 billion pounds acquisition of Dublin-based Shire Plc is backed with a 13.5 billion pounds ($23.03 billion) bridge loan, according to the company's filing with the Securities and Exchange Commission in the US.

18 Jul 2014

Shire rally props up UK's FTSE

LONDON, July 18 - A rise in drug maker Shire propped up Britain's stock market on Friday, cushioning it to an extent from concerns about the conflict in Ukraine, where a passenger plane was shot down over the rebel-controlled east.

18 Jul 2014

BUSINESS-NEWS-SCHEDULE AT 1230 GMT / 8.30 AM ET

Editor: Malcolm Davidson +44 20 7542 6958

18 Jul 2014

Housebuilders fall as Ukraine worries hit UK's FTSE

LONDON, July 18 - British stocks fell on Friday as investors sought safety after a passenger plane was shot down in Ukraine, reviving fears about the conflict there, while shares in housebuilders underperformed following a broker downgrade.

18 Jul 2014

BRIEF-Shire Q2 total revenue up 20 pct

* Shire delivers record quarterly revenues and non-GAAP diluted earnings per ads up 42 pct

18 Jul 2014

UPDATE 1-Market Chatter-Corporate finance press digest

(Adds items on Fujitsu, Shire, Fiat Chrysler, Advanstar, Bingham McCutchen, Sycamore Partners, ZF Friedrichshafen and Asciano)

18 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks